NCT01730079

Brief Summary

Background: \- Near-infrared spectroscopy (NIRS) is a functional imaging technique that can be uses light to study brain function while allowing for movement. To look at blood flow in the brain, NIRS uses a low-power light source with detectors that see how the light changes as it passes through brain tissue. Brain blood flow can indicate which parts of the brain are active during different tasks. Researchers want to study children with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) and will use NIRS to compare the blood flow in the brain of children with ADHD and ASD with that of typically developing children. Objectives:

  • To see how well NIRS can detect changes in brain blood flow during tests of thinking and memory in children.
  • To compare blood flow in the brains of typically developing children and those with ADHD or ASD. Eligibility: \- Children between 4 and 8 years of age with ASD, ADHD, or children with no psychiatric diagnoses. Design:
  • Participants will be screened for eligibility. Those who are taking stimulant medication for ADHD or ASD will need to stop taking it for 3 days before the study visit.
  • After participating in a screening assessment, all participants will have one study visit. At this visit, they will have be asked to complete two tasks during a NIRS scan. For both tasks, they will react to images on a computer screen. This visit will last about 2 hours.
  • This is a testing study only. No blood or other samples will be needed for this study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 23, 2012

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

November 17, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 21, 2012

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 11, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 11, 2017

Completed
Last Updated

October 18, 2019

Status Verified

April 11, 2017

Enrollment Period

4.5 years

First QC Date

November 17, 2012

Last Update Submit

October 17, 2019

Conditions

Keywords

Attention Deficit Hyperactivity DisorderAutismNear Infrared SpectroscopyBrain Activity

Outcome Measures

Primary Outcomes (1)

  • Graded changes in blood flow and oxygen, measured with NIRS, in response to different functional tasks.

Secondary Outcomes (1)

  • Differential activity according to region of the frontal cortext and task elements.

Eligibility Criteria

Age4 Years - 8 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children will be between 4 to 8 years of age (4 years, 0 months to 8 years, 11 months). English speakers only will be recruited for the study, because the language measures/tests and stimuli being used are in English and were developed and standardized on English-only samples.
  • Typically Developing Group:
  • Development in nonverbal and verbal areas within age expectations (per scores onthe Differential Ability Scales, Second Edition or the Wechsler Preschool and Primary Scale of Intelligence Fourth Edition , no more than 1.5 standard deviation below the mean)
  • ASD Group:
  • Diagnosis of Autistic Disorder, Asperger s disorder, or Pervasive Developmental Disorder - Not Otherwise Specified (PDD NOS), based on diagnostic evaluation conducted through a separate screening protocol
  • ADHD Group:
  • Diagnosis of ADHD based on diagnostic evaluation conducted through a separate screening protocol Minimum Nonverbal IQ of 80; Minimum Verbal IQ score of 60

You may not qualify if:

  • All children who meet the following criteria:
  • Primary language spoken at home is other than English
  • Any skin disease that affects the scalp
  • Past or present vascular disease, such as lupus, ankylosing spondylitis or scleroderma.
  • Known adverse reaction to latex
  • Presence or history of medical conditions known to affect cerebral anatomy, such as known cysts, arterivenous malformations or cortical tubers.
  • Head trauma with loss of consciousness lasting longer than 5 seconds in the last year or any evidence of functional impairment due to and persisting after head trauma
  • Motor movement disorder which may cause sudden excessive movement, such as Tourette s disorder
  • Birth before 32 weeks of gestation. Premature birth can have a profound effect on brain function and structure
  • A known neurological or neurogenetic condition affecting the central nervous system, such as epilepsy, cerebral palsy, neurofibromatosis, velo-cardiofacial syndrome.
  • Color blindness
  • Typically Developing Group:
  • Cognitive impairment, defined as Nonverbal IQ below 80, or signs of ASD or ADHD
  • Confirmed diagnosis of any DSM-IV-TR Axis I disorder
  • Taking medications for neuropsychiatric disorders such as antidepressants, antipsychotics, mood stabilizers, anxiolytics or any medication used to treat ADHD (psychostimulants, atomoxetine (Strattera ), bupropion (Wellbutrin ), tricyclic antidepressants (like impramine), clonidine, guanfacine, or modafinil (Provigil ).
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Boas DA, Dale AM, Franceschini MA. Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. Neuroimage. 2004;23 Suppl 1:S275-88. doi: 10.1016/j.neuroimage.2004.07.011.

    PMID: 15501097BACKGROUND
  • Carlsson J, Lagercrantz H, Olson L, Printz G, Bartocci M. Activation of the right fronto-temporal cortex during maternal facial recognition in young infants. Acta Paediatr. 2008 Sep;97(9):1221-5. doi: 10.1111/j.1651-2227.2008.00886.x.

    PMID: 18627358BACKGROUND
  • Elwell CE, Henty JR, Leung TS, Austin T, Meek JH, Delpy DT, Wyatt JS. Measurement of CMRO2 in neonates undergoing intensive care using near infrared spectroscopy. Adv Exp Med Biol. 2005;566:263-8. doi: 10.1007/0-387-26206-7_35.

    PMID: 16594161BACKGROUND

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivityAutistic DisorderAutism Spectrum Disorder

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersChild Development Disorders, Pervasive

Study Officials

  • Audrey E Thurm, Ph.D.

    National Institute of Mental Health (NIMH)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 17, 2012

First Posted

November 21, 2012

Study Start

October 23, 2012

Primary Completion

April 11, 2017

Study Completion

April 11, 2017

Last Updated

October 18, 2019

Record last verified: 2017-04-11

Locations